E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Invasive mold infections |
leucémie aigue myéloïde |
|
E.1.1.1 | Medical condition in easily understood language |
Invasive mold infections |
leucémie aigue myéloïde |
|
E.1.1.2 | Therapeutic area | Not possible to specify |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
will be to determine whether the absolute risk reduction (ARR) in the cumulative incidence of IMI in AML/MDSit patients is higher when the use of posaconazole versus fluconazole prophylaxis is allocated on a genetically predicted risk stratification to be at either high-risk or low-risk for IMI. Accordingly, the study aims to demonstrate a reduction in the number of patients needed-to-treat (NNT being the inverse of ARR) with antifungal prophylaxis to avoid one IMI event in high-risk compared to low-risk patients.
|
|
E.2.2 | Secondary objectives of the trial |
1. The cumulative incidence of possible IMI* by day 180 in the ITT population. 2. The cumulative incidence of probable and proven IFI*, namely: (a) all IFI, (b) IA only and (c) IC only in the ITT patient population by day 180. 3. The time to probable and proven IMI* during 180 days in the ITT population. 4. The overall survival in the ITT population by day 180. 5. The time to use and number of patient-days of amphotericin B or an echinocandin in the ITT population during 180 days. 6. The frequency and distribution of adverse events (AE) of interest in posaconazole and fluconazole treated participants in the ITT population during 180 days, namely (a) elevation of liver tests and (b) prolongation of QTc interval on ECG. 7. The cumulative incidence of probable and proven IFI*, namely: all IFI, all IMI, IA only and IC only in the per protocol (PP) population by day 180.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Signed informed consent according to national/local regulations 2. Age ≥18 years 3. Diagnosis of AML or MDSit (de novo or secondary) treated with an intensive chemotherapy regimen, including induction / consolidation / salvage chemotherapy 4. Planned hospital admission for the duration of the neutropenic phase (ANC<500 cells/mm3)
|
|
E.4 | Principal exclusion criteria |
1. Patients with neutropenia (ANC<500 cells/mm3) at hospital admission (first inpatient blood analysis) 2. Patients with a diagnosis of acute promyelocytic leukemia (APL) or AML-M3 3. Patients with known history of allergy, hypersensitivity or serious reaction to azole antifungals 4. Women who are pregnant (positive blood pregnancy test within 10 days before randomization) or breast feeding 5. Diagnosis and treatment for an IFI within 3 months prior to study enrolment and an IMI at any point prior to or at the time of enrolment 6. Severe liver dysfunction, defined as at least one of the following markers: AST, ALT, alkaline phosphatase, and/or total bilirubin above >5x upper limit of normality documented on the first inpatient analysis if still present at inclusion and considered contra-indicated by the clinical team 7. Patients with a prolonged QTc interval on at least 2 electrocardiograms (ECG): QTc greater than 450 msec for men and greater than 470 msec for women, and if considered contra-indicated by the clinical team 8. Patients who are receiving and cannot discontinue the following drugs at least 24 hours prior to randomization: terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine (because of the possibility of QT prolongation), sirolimus, rifampin, rifabutin, carbamazepine, long acting barbiturates (e.g., phenobarbital, mephobarbital), ritonavir, efavirenz, or ergot alkaloids (e.g., ergotamine, dihydroergotamine) 9. Serious uncontrolled concomitant disease or comorbidity that, in the opinion of the investigator, may compromise adherence to the study protocol 10. Receipt of a prior allogeneic HCT 11. Previous exposure to mold-active prophylaxis (>48 hours within 7 days of inclusion). 12. Patients with relapsed leukemia already included in the trial
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The cumulative incidence of proven and probable IMI* in the intention-to-treat (ITT) population by day 180. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Please enter information in English and add any other language that is ap180 daysplicable |
|
E.5.2 | Secondary end point(s) |
1. The cumulative incidence of possible IMI* by day 180 in the ITT population. 2. The cumulative incidence of probable and proven IFI*, namely: (a) all IFI, (b) IA only and (c) IC only in the ITT patient population by day 180. 3. The time to probable and proven IMI* during 180 days in the ITT population. 4. The overall survival in the ITT population by day 180. 5. The time to use and number of patient-days of amphotericin B or an echinocandin in the ITT population during 180 days. 6. The frequency and distribution of AE of interest in posaconazole and fluconazole treated participants in the ITT population during 180 days, namely: a) Hepatotoxicity, defined by elevation of at least one of the following markers above >5x upper limit of normal: transaminases, alkaline phosphatase and/or total bilirubin b) New QTc prolongation, defined as QTc >450 msec for men and >470 msec for women 7. The cumulative incidence of probable and proven IFI*, namely: all IFI, all IMI, IA only and IC only in the per protocol (PP) population by day 180.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 3 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 6 |